Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Closes $130M Notes Offering

NEW YORK (GenomeWeb News) – Sequenom said after the close of the market Monday that it has completed the private placement of $130 million of 5 percent convertible senior notes due 2017.

The San Diego-based molecular diagnostics firm said the placement included $20 million aggregate principal amount of notes from the full exercise of the over-allotment option.

Net proceeds from the offering will be used to fund further commercialization of Sequenom's MaterniT21 Plus non-invasive test for trisomies, 21, 18, and 13.

The notes placement follows a public offering of Sequenom common stock earlier this year that brought in $62 million in gross proceeds.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.